Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 03 Dec 2021 Results comparing (n=2932) hospitalization rates (all-cause and AD-related) of adults with atopic dermatitis treated with dupilumab versus control by post hoc analysis of 7 RCTs (NCT01548404, NCT02277743, NCT02277769, NCT01859988, NCTO2210780, NCT02755649 and NCT02260986), presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 07 May 2019 Results assessing the impact of dupilumab on infection rates in patients with moderate-to-severe AD using pooled data from 7 randomized trials, published in the American Journal of Clinical Dermatology
- 06 Aug 2018 Results (n=178) published in the Journal of the American Academy of Dermatology